Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Myoclonus dystonia and muscular dystrophy: ɛ-sarcoglycan is part of the dystrophin-associated protein complex in brain.

Waite AJ, Carlisle FA, Chan YM, Blake DJ.

Mov Disord. 2016 Nov;31(11):1694-1703. doi: 10.1002/mds.26738. Epub 2016 Aug 18.

2.

Dilated cardiomyopathy mutations in δ-sarcoglycan exert a dominant-negative effect on cardiac myocyte mechanical stability.

Campbell MD, Witcher M, Gopal A, Michele DE.

Am J Physiol Heart Circ Physiol. 2016 May 1;310(9):H1140-50. doi: 10.1152/ajpheart.00521.2015. Epub 2016 Mar 11.

3.

Characterization of WWP1 protein expression in skeletal muscle of muscular dystrophy chickens.

Imamura M, Nakamura A, Mannen H, Takeda S.

J Biochem. 2016 Feb;159(2):171-9. doi: 10.1093/jb/mvv084. Epub 2015 Aug 26.

4.

Sequencing, annotation and analysis of the Syrian hamster (Mesocricetus auratus) transcriptome.

Tchitchek N, Safronetz D, Rasmussen AL, Martens C, Virtaneva K, Porcella SF, Feldmann H, Ebihara H, Katze MG.

PLoS One. 2014 Nov 14;9(11):e112617. doi: 10.1371/journal.pone.0112617. eCollection 2014. Erratum in: PLoS One. 2015;10(2):e0117958.

5.

SERCA2a gene therapy can improve symptomatic heart failure in δ-sarcoglycan-deficient animals.

Bouyon S, Roussel V, Fromes Y.

Hum Gene Ther. 2014 Aug;25(8):694-704. doi: 10.1089/hum.2013.132.

6.

Genetic variation at the delta-sarcoglycan (SGCD) locus elevates heritable sympathetic nerve activity in human twin pairs.

Hightower CM, Zhang K, Miramontes-González JP, Rao F, Wei Z, Schork AJ, Nievergelt CM, Biswas N, Mahata M, Elkelis N, Taupenot L, Stridsberg M, Ziegler MG, O'Connor DT.

J Neurochem. 2013 Dec;127(6):750-61. doi: 10.1111/jnc.12346. Epub 2013 Jul 19.

7.

Use of a lower dosage liver-detargeted AAV vector to prevent hamster muscular dystrophy.

Rotundo IL, Lancioni A, Savarese M, D'Orsi L, Iacomino M, Nigro G, Piluso G, Auricchio A, Nigro V.

Hum Gene Ther. 2013 Apr;24(4):424-30. doi: 10.1089/hum.2012.121. Epub 2013 Apr 4.

8.

A delta-sarcoglycan gene polymorphism as a risk factor for hypertrophic cardiomyopathy.

Ordoñez-Razo RM, Garrido-Garduño MH, Pérez-Martínez RA, Ruiz VM, Herrera-Tepatlán E, Rodríguez-Cruz M, Jiménez-Vaca AL, Minauro-Sanmiguel F, Salamanca-Gómez FA.

Genet Test Mol Biomarkers. 2012 Aug;16(8):855-8. doi: 10.1089/gtmb.2011.0343. Epub 2012 Apr 23.

9.

Animal models of muscular dystrophy.

Ng R, Banks GB, Hall JK, Muir LA, Ramos JN, Wicki J, Odom GL, Konieczny P, Seto J, Chamberlain JR, Chamberlain JS.

Prog Mol Biol Transl Sci. 2012;105:83-111. doi: 10.1016/B978-0-12-394596-9.00004-4. Review.

10.

Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Saini-Chohan HK, Mitchell RW, Vaz FM, Zelinski T, Hatch GM.

J Lipid Res. 2012 Jan;53(1):4-27. doi: 10.1194/jlr.R012120. Epub 2011 Nov 7. Review.

11.

Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy.

Rotundo IL, Faraso S, De Leonibus E, Nigro G, Vitiello C, Lancioni A, Di Napoli D, Castaldo S, Russo V, Russo F, Piluso G, Auricchio A, Nigro V.

PLoS One. 2011;6(9):e24729. doi: 10.1371/journal.pone.0024729. Epub 2011 Sep 9.

12.

δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

Blain AM, Straub VW.

Skelet Muscle. 2011 Mar 17;1(1):13. doi: 10.1186/2044-5040-1-13.

13.

Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex.

Townsend D, Yasuda S, McNally E, Metzger JM.

FASEB J. 2011 Sep;25(9):3106-14. doi: 10.1096/fj.10-178913. Epub 2011 Jun 10.

14.

Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations.

Cacciottolo M, Numitone G, Aurino S, Caserta IR, Fanin M, Politano L, Minetti C, Ricci E, Piluso G, Angelini C, Nigro V.

Eur J Hum Genet. 2011 Sep;19(9):974-80. doi: 10.1038/ejhg.2011.70. Epub 2011 Apr 27.

15.

Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters.

Hoshijima M, Hayashi T, Jeon YE, Fu Z, Gu Y, Dalton ND, Ellisman MH, Xiao X, Powell FL, Ross J Jr.

Circ Heart Fail. 2011 Jan;4(1):89-97. doi: 10.1161/CIRCHEARTFAILURE.110.957258. Epub 2010 Oct 29.

16.

Ca2+/calmodulin-dependent kinase IIdelta causes heart failure by accumulation of p53 in dilated cardiomyopathy.

Toko H, Takahashi H, Kayama Y, Oka T, Minamino T, Okada S, Morimoto S, Zhan DY, Terasaki F, Anderson ME, Inoue M, Yao A, Nagai R, Kitaura Y, Sasaguri T, Komuro I.

Circulation. 2010 Aug 31;122(9):891-9. doi: 10.1161/CIRCULATIONAHA.109.935296. Epub 2010 Aug 16.

17.
18.

Dystroglycan matrix receptor function in cardiac myocytes is important for limiting activity-induced myocardial damage.

Michele DE, Kabaeva Z, Davis SL, Weiss RM, Campbell KP.

Circ Res. 2009 Nov 6;105(10):984-93. doi: 10.1161/CIRCRESAHA.109.199489. Epub 2009 Sep 24.

19.
20.

Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments.

Vitiello C, Faraso S, Sorrentino NC, Di Salvo G, Nusco E, Nigro G, Cutillo L, Calabrò R, Auricchio A, Nigro V.

PLoS One. 2009;4(3):e5051. doi: 10.1371/journal.pone.0005051. Epub 2009 Mar 31.

Supplemental Content

Support Center